Entrada Therapeutics Inc (TRDA)
14.19
+0.19
(+1.36%)
USD |
NASDAQ |
Jul 03, 16:00
Entrada Therapeutics Research and Development Expense (TTM): 105.39M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 105.39M |
| December 31, 2023 | 99.88M |
| September 30, 2023 | 87.28M |
| June 30, 2023 | 84.04M |
| March 31, 2023 | 73.99M |
| December 31, 2022 | 66.61M |
| Date | Value |
|---|---|
| September 30, 2022 | 63.29M |
| June 30, 2022 | 54.84M |
| March 31, 2022 | 45.42M |
| December 31, 2021 | 35.93M |
| September 30, 2021 | 30.22M |
| June 30, 2021 | 25.41M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
25.41M
Minimum
Jun 2021
105.39M
Maximum
Mar 2024
64.36M
Average
64.95M
Median
Research and Development Expense (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 92.17M |
| Vertex Pharmaceuticals Inc | 3.209B |
| Sarepta Therapeutics Inc | 832.10M |
| PTC Therapeutics Inc | 587.57M |
| GlycoMimetics Inc | 20.68M |